First Targeted Drug Approved for Blistering Skin Condition

(MedPage Today) -- The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced.
Approval of the injectable...